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To clarify the mechanism underlying the described U-shaped relation of both low and high
levels of IGF-1 with cardiovascular disease this study explores the effect of decreasing and
increasing growth hormone dose in GH deficient adults on (micro)vascular function, body
composition and insulin resistance. In this randomized clinical trial, thirty-two subjects
receiving GH therapy with an IGF-1 concentration between −1 and 1 SD score (SDS) for at
least one year were randomized to receive either a decrease (IGF-1 target level of −2 to −1
SDS) or an increase of their daily GH dose (IGF-1 target level of 1 to 2 SDS) for a period of
24 weeks. Microvascular endothelium (in)dependent vasodilatation and vasomotion,
vascular stiffness by pulse wave analysis, and HOMA-IR were measured. At the end of
the study 30 subjects (65.6% men, mean age 46.6 (SD 9.9) years) were analyzed. There
was a favorable effect of increasing the IGF-1 level on waist circumference compared to
decreasing the IGF-1 level (p=0.05), but a detrimental effect on insulin resistance (p=0.03).
Decreasing IGF-1 level significantly lowered the endothelial domain of vasomotion
(p=0.03), whereas increasing IGF-1 level increased the contribution of the neurogenic
domain (p=0.05). This change was related to the favorable change in waist circumference.
In conclusion, increasing IGF-1 levels was beneficial for body composition but detrimental
with respect to insulin resistance. The contribution of the neurogenic vasomotion domain
increased in parallel, and could be explained by the favorable change in
waist circumference.
Clinical Trial Registration: ClinicalTrials.gov, identifier NCT01877512.
Keywords: growth hormone, insulin-like growth factor-1, growth hormone deficiency in adults, insulin resistance,
vasomotion, vascular endothelium, growth hormone treatment
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INTRODUCTION
Epidemiological evidence for a bidirectional link between serum
IGF-1 concentrations and cardiovascular disease (CVD) has
been repeatedly demonstrated. On the one hand, growth
hormone (GH) deficient adults are characterized by an adverse
lipid profile and altered body composition with increased fat
mass which may put them on an increased risk for cardiovascular
disease (1, 2). Moreover, even low-normal IGF-1 levels have been
associated with the development of ischemic heart disease and
stroke in the general population (3–5). On the other hand, high
levels of IGF-1 such as observed in acromegaly are also
associated with an adverse cardiovascular risk profile and a
higher prevalence of CVD (6). These data suggest a U-shaped
relationship between IGF-1 concentrations and CVD, which was
corroborated by the finding of a U-shaped relationship with
cardiovascular mortality in a Dutch cohort of healthy older
people (7). Presently, it is unclear whether such a U-shaped
association also exists in GH deficient adults treated with GH.
Many studies demonstrate favorable effects of GH replacement
therapy in adults with GH deficiency (8, 9), and of normalization
of GH and IGF-1 levels in acromegaly (10), on cardiovascular
risk factors, but the presented data suggest that there may be an
optimal target level of IGF-1. In addition, the underlying
mechanisms of this U-shaped relationship remain unresolved.
On the one hand, IGF-1 is postulated to protect against (micro)
vascular endothelial dysfunction, atherosclerotic plaque
development, and ischemic myocardial damage (11).
Interestingly, cultured endothelial cells, isolated microvessels,
as well as the capillaries of perfused hearts, all possess distinct
surface binding sites for both IGF-1 and insulin (12). Capillary
density has been shown to be lower in untreated GH deficient
patients than in control subjects, which increased to a level that
was not different from that in control subjects after GH
treatment normalized plasma IGF-1 (13). On the other hand,
high levels of IGF-1 such as observed in acromegaly are
associated with profound insulin resistance (6), which may
offset the beneficial (micro)vascular effects of IGF-1. Insulin
resistance itself has been linked to a lower capillary density
and a change in vasomotion, the rhythmic change in vascular
diameter, which is thought to influence capillary perfusion (14).
In order to elucidate possible mechanisms underlying the U-
shaped relationship of IGF-1 with CVD, the aim of the present
study is to explore the effects of titrating GH dose to low-normal or
high-normal levels of IGF-1 for 24 weeks in GH deficient adults on
(micro)vascular function, body composition and insulin resistance.
MATERIALS AND METHODS
Study Design
This study presents data from a randomized, open-label, clinical
trial conducted at one university hospital (VU University
Medical Center, Amsterdam, The Netherlands) comparing
decreasing and increasing GH dose for 24 weeks. The study
investigates the efficacy and safety measures of GH replacement
therapy before and after reaching low-normal and high-normal
IGF-1 target levels (15). At entry subjects were receiving GH
treatment according to general clinical practice (daily
subcutaneous somatropin injections using automated pen
systems manufactured by Pfizer Inc., Novo Nordisk Inc., and
Eli Lilly and Co.). Subjects were selected based on having an IGF-
1 concentration between −1 and 1 SDS (adjusted for age and
gender) during GH replacement therapy. Randomization was
done by a computer-generated random sequence and was
stratified by gender. Subjects were randomized to receive either
a decrease of their regular dose of GH treatment (IGF-1 target
level of –2 to –1 SDS) (low dose=LD group), or an increase of
their regular dose (IGF-1 target level of 1 to 2 SDS) (high
dose=HD group), for 24 weeks. After 4 weeks the GH dose
was adjusted when the target level of IGF-1 was not reached. At
visit one (baseline) and visit two (after 24 weeks) blood samples
were drawn and measurements performed to assess micro- and
macrovascular function.
Patients
The study group consisted of 32 adult patients with documented
severe GH deficiency and more than one year of GH treatment,
with an IGF-1 level between −1 and 1 SD score (SDS) for at least six
months. Other pituitary hormone deficiencies had to be substituted
when indicated and be stable for at least six months and during
follow up. Severe GH deficiency was diagnosed prior to the study
and defined according to the consensus guidelines of the GH
Research Society for the diagnosis and treatment of adults with
GH deficiency (16). In the Netherlands, the approval of GH
treatment (and reimbursement of costs by the health insurer) was
judged by an independent board of endocrinologists wanting to see
two abnormal GH stimulation tests (mostly used: insulin-tolerance
test and GHRH-arginin test) or one abnormal test or low IGF-1 in
combination with panhypopituitarism or profound congenital GH
deficiency. Patients were not eligible if they had a recent or current
malignancy, craniopharyngioma as cause of hypopituitarism, were
(planning to become) pregnant, or had a cardiovascular event
within the last year before recruitment. Patients with prior
Cushing’s disease or acromegaly were not excluded since an
earlier study did not demonstrate significant interaction with the
effect of GH treatment on cardiovascular mortality in GH deficient
adults in The Netherlands (17). Patients were included after oral
and written informed consent. The study protocol was approved by
the Ethics Committee of the VU University Medical Center,
Amsterdam. The study was performed according to Good
Clinical Practice and the Declaration of Helsinki. This study is
registered with ClinicalTrials.gov, number NCT01877512.
Laboratory Investigations
Laboratory investigations included total IGF-1, and insulin and
glucose to calculate insulin resistance by HOMA-IR. Blood
samples were drawn after an overnight fast prior to every visit.
Total IGF-1 was measured by a non-competitive (sandwich)
chemiluminescence immunoassay (Liaison, DiaSorin S.p.A.,
Italy). The inter-assay coefficient of variation (CV) was 7.4%.
Insulin was measured by an immunometric assay, Luminescence
(Advia Centaur, Siemens Medical Solutions Diagnostics, USA).
The inter-assay coefficient of variation (CV) was 8%.
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Microvascular Function
Endothelial function was assessed by microvascular measurements
of the skin blood flow including endothelium (in)dependent
vasodilatation and vasomotion. Endothelium-(in)dependent
vasodilation of finger skin microcirculation was evaluated by
measuring skin blood flow in perfusion units (PU) by a laser
Doppler system (Periflux 4000, Perimed, Stockholm, Sweden) in
combination with iontophoresis of acetylcholine (ACh) and
sodium nitroprusside (SNP), respectively, as described previously
(18). All measurements were performed in the fasting state, in the
sitting position with the investigated hand at heart level in a
temperature-controlled room. Skin temperature was registered
continuously and was above 28°C at the start of all
microvascular measurements. ACh (1% Miochol; Bournonville
Pharma, Braine d’Alleud, Belgium) was delivered to the skin on
the middle phalanx of the third finger using an anodal current,
consisting of seven doses (0.1 mA for 20 s) with a 60 s interval
between each dose. SNP (0.01%, Nipride; Roche, Woerden, The
Netherlands) was delivered on the middle phalanx of the second
finger using a cathodal current, consisting of seven doses (0.2 mA
for 20 s) with a 90 s interval between each dose. In order to perform
vasomotion analyses skin blood flow was measured during 30 min
with a laser Doppler probe positioned at the dorsal side of the wrist
of the arm. A bandpass filter with cut-off frequencies at 20 Hz and
20 kHz, and a time constant of 0.2 s, was selected. Wavelet analysis
of the signals with a minimum of 30 min (with a sampling
frequency of 32 Hz resulting in approximately 58.000 data
points) in length was conducted to assess the frequency
spectrum between 0.01 and 1.6 Hz. Wavelet analysis was
performed using the wavelet toolbox in Matlab (7.8.0.347; The
Mathworks, Inc., Natick, MA, USA), as described earlier (19).
Scales are chosen for a resulting frequency range from 0.01 to
1.6 Hz which can be divided in five frequency intervals as
described by Stefanovska et al. (20). The first three lower
frequencies are locally generated; 0.01–0.02 Hz as endothelial
activity, 0.02–0.06 Hz as neurogenic activity, and 0.06–0.15 Hz
as myogenic response of the vascular smooth muscle cells
(VSMC). The higher frequencies originate upstream and are:
0.15–0.4 Hz as respiratory function and 0.4–1.6 Hz as heart beat
frequency. To eliminate edge effects, the first and last 2,000
samples were removed from the resulting wavelet transform.
The relative amplitude was calculated for each of the five
frequency bands by dividing the average amplitude within a
band by the average amplitude of the entire spectrum. This
normalization takes into account the variation in the signal




Blood pressure and heart rate were measured automated by
Dinamap (PRO 100 V2), with a proper sized cuff, after 3 min of
rest, three times with at least 1 min in between, where the two last
measurements were averaged. Vascular stiffness was assessed by
Pulse Wave Analysis, determining pulse wave velocity (PWV) and
augmentation index (AIx) by a validated noninvasive automated
device. The Sphygmocor Pulse Wave Velocity system uses
applanation tonometry in conjunction with a three-lead ECG to
take sequential measurements at two arterial sites. The timing of
the onset of systole of the pressure waves were compared with the
timing of the corresponding R waves on the ECG recording, with
the same delay calculated by the software. PWV was calculated as
the ratio of the distance traveled and the foot-to-foot time delay
between pulse waves and expressed in meters per second. A high
fidelity peripheral artery blood pressure waveform at the radial
artery is used to calculate the AIx. The cardiac index (l/min/m2) at
rest was determined by a non-invasive continuous hemodynamic
monitoring system (Nexfin monitoring system, BMEYE B.V.,
Amsterdam, The Netherlands).
Statistical Analyses
Categorical data were expressed as number (percentage) and
continuous data as mean (SD), or as median (interquartile range
(IQR)) for skewed variables. Parametric or non-parametric tests
were used when appropriate. General Linear Model (GLM) for
repeated measures was used for between-group differences for
change over time. Skewed variables were transformed when
needed. Adjustments for baseline value were conducted to
account for regression to the mean for the different outcome
measures. Moreover, at baseline the LD and HD groups differed
with respect to childhood onset (CO) and adult onset (AO) GH
deficiency, and this variable was therefore added as covariate to
the final GLMs. Subsequently, linear regression analyses were
performed to investigate whether the association of change in
IGF-1 SDS with some domains of the vasomotion analysis
remained when adjusting for relevant covariates. Data were
examined by use of Pearson’s correlation. Two sided P values
of 0.05 or less were considered significant. Statistical analyses
were performed by the statistical software package IBM SPSS
statistics 20.0 (SPSS Inc., Chicago, IL).
RESULTS
Between May 31, 2013, and April 11, 2014, we enrolled 32
patients. One subject withdrew after start of the study because
of personal reasons. Another subject was excluded from the
analyses due to the inability to reach the proper IGF-1 target
level. The final analyses were conducted with 15 subjects in each
group. Table 1 shows the baseline characteristics of the groups.
There were more subjects with CO GH deficiency in the LD
group and consequently fewer patients with a history of pituitary
surgery. This corresponds with the underlying diagnosis of GH
deficiency being 50% congenital in the LD group (compared to
19% in the HD group) and 50% (treatment of) pituitary tumor in
the HD group (compared to 25% in the LD group). Of all 13
pituitary tumors, six concerned a non-secreting adenoma, five a
prolactinoma, and two an ACTH producing adenoma.
The median daily dose of GH was decreased from 0.25 (IQR
0.35) to 0.10 (IQR 0.15) mg/day (p<0.001) in the LD group and
increased from 0.25 (IQR 0.30) to 0.50 (IQR 0.60) mg/day
(p<0.001) in the HD group. The IGF-1 concentration
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decreased from 21.40 (SD 4.87) at baseline to 12.43 (SD 2.25)
nmol/L (p<0.001) in the LD group after 24 weeks, and increased
from 18.53 (SD 2.77) to 28.13 (SD 5.15) nmol/L (p<0.001) in the
HD group (Figure 1 shows the IGF-1 levels in SDS adjusted for
age and gender).
The effects of increasing or decreasing IGF-1 levels on body
composition, macrovascular hemodynamics and vascular
stiffness and insulin resistance are presented in Table 2. In
parallel to the favorable effect of increasing the IGF-1 level on
waist circumference compared to decreasing the IGF-1 level
(p=0.05), there was a significant difference in the effect on
insulin resistance (p=0.03). Increasing IGF-1 by augmenting
the GH dose in the HD group significantly increased insulin
resistance compared to baseline (1.12 vs. 0.79, p=0.01), whereas
no significant change was detected during decreased levels of
IGF-1 (0.74 vs. 0.80, p=0.24). With respect to microvascular
function, no (difference in) effect on endothelial-dependent, nor
endothelial-independent, vasodilatation was found. Decreasing
IGF-1 level significantly lowered the endothelial domain of
vasomotion (p=0.03). Increasing IGF-1 level increased the
contribution of the neurogenic domain (p=0.05) (Figure 2).
Correlation analyses (Figure 3) demonstrated that the change
in waist circumference was inversely correlated with the change
in the neurogenic vasomotion domain (r −0.39, p<0.05), but not
with change in IGF-1 SDS or HOMA-IR. In addition, the change
in IGF-1 SDS was positively correlated with the change in the
endothelial vasomotion domain (r 0.38, p<0.05), but not with
changes in waist circumference or HOMA-IR. Subsequently,
these associations and possible confounders were explored in
the regression models presented in Table 3.
DISCUSSION
This exploratory study on the possible mechanisms linking IGF-
1 and CVD investigated the effect on (micro)vascular function,
body composition and insulin resistance of changing the IGF-1
concentration to low- or high-normal levels during GH
treatment in GH deficient adults. The most clear finding was
that increasing the GH dose to a high-normal IGF-1 level led to a
significant increase in insulin resistance, but a reduction in waist
circumference. Moreover, although the overall effect on (micro)
vascular function was limited, both the neurogenic and
TABLE 1 | Baseline characteristics of the low dose group in which the IGF-1
target level was between −2 and −1 standard deviation score (SDS), and the
high dose group in which the IGF-1 target level was between 1 and 2 SDS.
Low Dose High Dose P value
No. of patients 16 16
Age, year 47.4 (10.8) 46.4 (9.3) 0.80
Sex, no. of females (%) 6 (37.5) 5 (31.2) 0.71
Onset of GHD, CO (%) 10 (62.5) 3 (18.8) 0.01
Cranial radiotherapy (%) 1 (6.2) 2 (12.5) 1.00
Pituitary surgery (%) 2 (12.5) 8 (50.0) 0.02
Isolated GHD (%) 4 (25) 4 (25) 1.00
TSH deficiency (%) 8 (50) 11 (68.8) 0.28
LH/FSH deficiency (%) 10 (62.5) 7 (43.8) 0.29
ACTH deficiency (%) 10 (62.5) 10 (62.5) 1.00
ADH deficiency (%) 0 4 (25) 0.10
Cardiovascular disease (%) 3 (18.8) 4 (25) 1.00
Diabetes mellitus (%) 3 (18.8) 0 0.23
Smoking (%) 4 (25) 2 (12.5) 0.65
GH dose, mg/daya 0.23 (0.36) 0.28 (0.30) 0.93
Duration GH treatment, yeara 15.1 (17.9) 12.6 (12.7) 0.09
Values are mean (SD) unless stated otherwise.
aMedian (IQR).
GHD, growth hormone deficiency; CO, childhood onset; GH, growth hormone.
FIGURE 1 | Mean serum total IGF-1 level in SD score (± SEM) at baseline, after four weeks of growth hormone (GH) treatment and at end of follow up in the low
dose (dashed line) and high dose (solid line) group.
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endothelial vasomotion domain were affected by a change in the
GH dose. Interestingly, insulin resistance and (central) obesity
have been demonstrated to be associated with a decreased
activity of the neurogenic and endothelial vasomotion domain
(22). In the present study, however, the changes in insulin
resistance and the vasomotion domains were disconcordant,
i.e. insulin resistance became worse, whereas the contribution
of the neurogenic and endothelial vasomotion domains increased
after increasing the GH dose to a high-normal IGF-1 level. The
changes in vasomotion seem, in part, to parallel the changes in
waist circumference.
Vasomotion is the rhythmic change in vascular diameter
which is thought to influence capillary density and capillary
exchange of substances between blood and tissues (23). As
already mentioned IGF and insulin receptors can be detected
on the microvascular endothelium, and therefore IGF and
insulin should in theory be able to influence microvascular
vasomotion. Indeed, insulin has been shown to alter arteriolar
vasomotion with a resultant increase in the capillary exchange
surface (14, 24, 25). Systemic hyperinsulinemia affects
vasomotion by increasing neurogenic and endothelial activity
in skin, and the change in the neurogenic vasomotion domain is
TABLE 2 | The effect of increasing or decreasing IGF-1 level on measurements of body composition, insulin resistance, and macrovascular hemodynamics and
vascular stiffness.
Low Dose High Dose P value for between group differencea
Baseline Follow up Baseline Follow up
BMI, kg/m2 28.2 (9.8) 28.2 (9.4) 28.8 (4.2) 28.4 (3.3) 0.47
Waist circumference, cm b 97 (24) 99 (23) 105 (11) 102 (8) 0.05
Insulin resistance (HOMA-IR)c 0.80 (1.24) 0.74 (1.48) 0.79 (0.57) 1.12 (0.88)* 0.03
Fasting glucose, mmol/L 4.3 (0.7) 4.5 (1.2) 4.3 (0.9) 4.7 (0.6) 0.54
Insulin, pmol/L c 43 (77) 40 (86) 42 (34) 62 (48)* 0.01
Total cholesterol, mmol/L 5.02 (1.01) 4.86 (0.75) 5.15 (0.98) 4.99 (1.02) 0.90
HDL cholesterol, mmol/L 1.51 (0.53) 1.54 (0.51) 1.47 (0.40) 1.50 (0.43) 0.63
LDL cholesterol, mmol/L 3.04 (0.88) 2.86 (0.56) 3.10 (0.94) 2.92 (0.79) 0.93
Triglycerides, mmol/L 1.03 (0.38) 1.03 (0.40) 1.27 (0.59) 1.33 (0.45) 0.65
Free fatty acid, mmol/L 0.42 (0.18) 0.42 (0.19) 0.45 (0.22) 0.51 (0.22) 0.58
Systolic blood pressure, mmHg 129 (18) 127 (12) 126 (14) 124 (16) 0.71
Diastolic blood pressure, mmHg 80 (8) 78 (8) 77 (9) 74 (10) 0.42
Heart rate, beats/min 68 (8) 63 (8)* 59 (8) 61 (9) 0.54
Cardiac index, liter/min/m2 3.0 (0.5) 3.0 (0.7) 2.7 (0.5) 2.9 (0.4) 0.36
Pulse Wave Velocity, m/s 7.2 (1.0) 7.2 (0.7) 7.1 (1.2) 7.1 (1.5) 0.76
Augmentation index 24 (18) 25 (17) 20 (15) 17 (11) 0.17
Values are mean (SD) unless stated otherwise.
aThe effect in both groups (delta) are compared and adjusted for baseline value and onset of GHD, bWaist circumference reference value men <102 cm, women <88 cm, cMedian (IQR),
*P value < 0.05 for change from baseline.
FIGURE 2 | The contribution of different frequency intervals to microvascular vasomotion (expressed in energy density) by laser Doppler of skin blood flow in both
treatment groups before and after 24 weeks. The frequency intervals are: 0.4–1.6 Hz = cardiac function, 0.15–0.4 Hz = respiratory function, 0.06–0.15 Hz =
myogenic response of the vascular smooth muscle cells, 0.02–0.06 Hz = neurogenic activity, 0.01–0.02 Hz = endothelial activity.
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directly associated with the increase in capillary density during
hyperinsulinemia (14, 25). Moreover, in obese, insulin-resistant
subjects, the contribution of the neurogenic and endothelial
vasomotion domains is impaired (22). Data on the effects of GH
on vasomotion are presently lacking, but the finding that GH
replacement therapy is able to increase capillary density in a
similar fashion as insulin, suggests that IGF-1 may influence
vasomotion. Indeed, in the present study, increasing IGF-1 level
leading to significantly more insulin resistance but a lower waist
circumference, resulted in more neurogenic activity, whereas
decreasing IGF-1 levels resulted in less endothelial activity in
the vasomotion analysis. However, increasing IGF-1 levels did
result in a reduction in waist circumference, which could have
had a favorable effect on the microcirculation. These results
are in line with previous studies investigating microvascular
vasomotion. De Jongh et al. found that the contribution of the
A
B
FIGURE 3 | Associations between change in the activity of the neurogenic vasomotion domain and waist circumference [(A); r −0.39, p<0.05] and the change in the
activity endothelial vasomotion domain and IGF-1 standard deviation score (SDS) [(B); r 0.38, p<0.05].
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frequency spectrum of the neurogenic activity to vasomotion
was lower in obese compared to lean women (22). De Boer et al.
demonstrated an inverse association of body mass index and
trunk fat with the neurogenic vasomotion domain in a different
cohort (21). However, these studies were both cross-sectional.
This study now demonstrates that by changing waist
circumference (by changing IGF-1 level) the neurogenic
domain of vasomotion is affected, which strengthens this
finding. Next to the change in neurogenic activity, decrease in
IGF-1 level in our study led to a decreased contribution of the
endothelial activity to the vasomotion, which seemed to be
independent of change in waist circumference or insulin
resistance. Consequently, this appears to be a direct effect of
low IGF-1, perhaps due to the decreased formation of NO (26).
Studies on the effect of IGF-1 on endothelial function are
scarce. Endothelial cells have high-affinity IGF-1 binding sites
and IGF-1 stimulates NO formation by endothelial cells and
VSMCs (27). Christ et al. demonstrated in patients with GH
deficiency that GH treatment had a beneficial effect on
endothelial function (measured by using venous occlusion
plethysmography before and after infusion of ACh and of
SNP) mediated by endothelium-dependent NO production
and/or increase in sensitivity of VSMC to NO (28). One
might have expected also an improvement of endothelial
function and arterial stiffness in the present study due to the
effect of raising NO formation by increasing IGF-1 levels. The
lack of effect could be due to sample size and limited follow up
time in which the IGF-1 levels were adjusted in a relative small
width. Rossi et al. (23) also suggest that skin vasomotion
investigation is a more sensitive evaluation of microvascular
endothelial function than skin blood flow measurements,
explaining that in our study the effect on endothelial function
was first demonstrated in the vasomotion measurements after
change of GH dose.
This is one of the first studies to explore possible
mechanisms for the association of IGF-1 levels within the
normal range with cardiovascular risk factors in GH treated
GH deficient adults. As mentioned above, a limitation of
the study is the overlapping effects of both higher GH doses
and higher IGF-1 level which could have influenced the results,
for instance with respect to dose-dependent effect of GH
on insulin resistance (29). Another factor to take into account
when interpreting the results is the total number of statistical
tests performed in a relatively small sample. Some of the
findings could have been due to chance alone. However,
most changes were in the expected direction and a larger
sample size or prolonged duration of the intervention with
proper adjustments for multiple testing could be expected to
demonstrate similar results.
In conclusion, in this exploratory study to elucidate possible
mechanism underlying the U-shaped relationship of IGF-1
with CVD, we demonstrated that higher IGF-1 levels are
beneficial for body composition but seem to be detrimental
with respect to insulin resistance. The contribution of the
neurogenic vasomotion domain increased in parallel, and
could be explained by the favorable change in waist
circumference. It remains to be seen whether the effects on the
neurogenic vasomotion domain are indeed beneficial for
capillary perfusion and cardiovascular homeostasis, and
therefore can be considered a measure of optimal IGF-1 levels.
Since the really long-term effect of high-normal IGF-1 target
levels during GH treatment remain to be investigated, and also
the known suggested association with tumor progression, no
clear recommendation on dosing strategy can be given at
this moment.
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